Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
23. Oktober 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
08. Oktober 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
04. Oktober 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
26. September 2024 17:26 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
19. September 2024 08:00 ET
|
Humacyte, Inc
- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies support the potential of the BVP to deliver insulin-producing islets as a...
Humacyte to Participate at Upcoming Investor Conferences in September
03. September 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
27. August 2024 08:00 ET
|
Humacyte, Inc
- Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting the ATEV was observed to have 12-month patency of 87.1% - -...
Humacyte Second Quarter 2024 Financial Results and Business Update
13. August 2024 07:00 ET
|
Humacyte, Inc
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma- -Reported Positive Topline Results from Phase 3 Trial of...
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
12. August 2024 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
09. August 2024 16:05 ET
|
Humacyte, Inc
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET – DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage...